ONCY insider buying and SEC filings, explained
Oncolytics Biotech Inc. · CIK 1129928
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$350K
Insiders who bought
9
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 12, 2026 | Purchase (code P) | Jared Kelly (CEO and Director) bought 5,050 shares at $0.9600 ($5K), reported as a purchase (code P). Holdings up 5% to 114,050 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Purchase (code P) | James T. Parsons (Director) bought 10,000 shares at $1.03 ($10K), reported as a purchase (code P). Holdings up 31% to 41,849 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Wayne Pisano (Director) bought 30,000 shares at about $0.8400 ($25K), reported as a purchase (code P). Holdings up 6% to 492,414 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Kirk Look (CFO) bought 12,000 shares at $0.8400 ($10K), reported as a purchase (code P). Holdings up 4% to 287,515 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Thomas Charles Heineman (Chief Medical Officer) bought 12,132 shares at $0.8300 ($10K), reported as a purchase (code P). Holdings up 4% to 282,818 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Allison Hagerman (VP, Product Development) bought 10,000 shares at $0.8300 ($8K), reported as a purchase (code P). Holdings up 10% to 115,059 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Deborah Margaret Brown (Director) bought 25,000 shares at about $0.8500 ($21K), reported as a purchase (code P). Holdings up 29% to 109,851 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Purchase (code P) | Patricia S Andrews (Director) bought 35,400 shares at about $0.8600 ($30K), reported as a purchase (code P). Holdings up 83% to 78,128 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 11–12, 2026 | Purchase (code P) | Bernd R. Seizinger (Director) bought 100,000 shares between Feb 11 and Feb 12 at about $0.8380 ($84K), reported as a purchase (code P). Holdings up 21% to 566,991 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 11–12, 2026 | Purchase (code P) | Jared Kelly (CEO and Director) bought 35,100 shares between Feb 11 and Feb 12 at about $0.8400 ($29K), reported as a purchase (code P). Holdings up 47% to 109,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 11, 2026 | Purchase (code P) | Andrew Aromando (Chief Business Officer) bought 29,600 shares at about $0.8600 ($25K), reported as a purchase (code P). Holdings up 116% to 55,100 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Jan 16, 2026 | Purchase (code P) | Bernd R. Seizinger (Director) bought 100,000 shares at about $1.04 ($104K), reported as a purchase (code P). Holdings up 27% to 466,991 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
9 insiders bought in 30 days
$350K in purchases since Jan 16, 2026 · Purchases traded Jan 16, 2026 to Mar 11, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Bernd R. Seizinger (Director) | $104K | Jan 16, 2026 | SEC filing |
| Andrew Aromando (Chief Business Officer) | $25K | Feb 11, 2026 | SEC filing |
| Jared Kelly (CEO) | $29K | Feb 12, 2026 | SEC filing |
| Bernd R. Seizinger (Director) | $84K | Feb 12, 2026 | SEC filing |
| Patricia S Andrews (Director) | $30K | Feb 12, 2026 | SEC filing |
| Deborah Margaret Brown (Director) | $21K | Feb 12, 2026 | SEC filing |
| Thomas Charles Heineman (Chief Medical Officer) | $10K | Feb 12, 2026 | SEC filing |
| Kirk Look (CFO) | $10K | Feb 12, 2026 | SEC filing |
| Wayne Pisano (Director) | $25K | Feb 12, 2026 | SEC filing |
| James T. Parsons (Director) | $10K | Mar 11, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ONCY in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.